STOCK TITAN

Teleflex Incorporated - TFX STOCK NEWS

Welcome to our dedicated page for Teleflex Incorporated news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex Incorporated stock.

Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.

The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.

Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.

The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.

Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.

In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.

Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.

For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.

Rhea-AI Summary
Teleflex Incorporated's Chairman, President, and CEO, Liam Kelly, will be speaking at the Jefferies London Healthcare Conference on November 14, 2023. The conference presentation will be available via a live audio webcast on the Teleflex website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences
-
Rhea-AI Summary
Teleflex Incorporated to host conference call for third quarter financial results and operational update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
-
Rhea-AI Summary
Teleflex completes acquisition of Palette Life Sciences, adding Barrigel® to its Interventional Urology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
Rhea-AI Summary
Teleflex Incorporated selected to exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at Vizient Innovative Technology Exchange. Products improve clinical outcomes and enhance safety in healthcare delivery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
Rhea-AI Summary
Teleflex survey shows that symptoms of enlarged prostate can disrupt travel plans and decrease enjoyment, with 23% of men choosing specific routes for bathroom availability. BPH can cause lower urinary tract symptoms and negatively impact quality of life. Only 49% of respondents have seen a urologist despite 95% feeling it's important to be informed about men's health. UroLift™ System is a minimally invasive treatment option for BPH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
Rhea-AI Summary
Liam Kelly, CEO of Teleflex, to speak at Morgan Stanley conference on Sep 13. Live webcast available on teleflex.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
Rhea-AI Summary
Teleflex announces release of Arrow ErgoPack Complete Kits with Hemodialysis and Large Bore catheters in the US, streamlining insertion workflow for clinicians and providing more options. Expansion includes clinician-inspired updates and meets recommendations of CDC, SHEA, INS, and OSHA guidelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) declares $0.34 quarterly cash dividend, payable on September 15, 2023, to shareholders of record on August 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
dividends
-
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) announced Q2 2023 financial results, with revenues of $743.3 million, up 5.5% YoY, and diluted EPS of $2.35. The company raised its 2023 revenue growth guidance to 5.80% to 6.55% and maintained adjusted diluted EPS guidance of $13.00 to $13.60. The acquisition of Palette Life Sciences AB is expected to contribute meaningfully to growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) announces FDA clearance for expanded use of QuikClot Control+™ Hemostatic Device in cardiac surgical procedures, offering a new solution for intraoperative bleeding control. The device also received expanded intended uses to include patients on anticoagulation/antiplatelet medication, use with or without autotransfusion equipment, and use with or without cardiopulmonary bypass systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags

FAQ

What is the current stock price of Teleflex Incorporated (TFX)?

The current stock price of Teleflex Incorporated (TFX) is $190.64 as of November 21, 2024.

What is the market cap of Teleflex Incorporated (TFX)?

The market cap of Teleflex Incorporated (TFX) is approximately 8.8B.

What does Teleflex Incorporated do?

Teleflex Incorporated is a global provider of specialty medical devices for critical care and surgical procedures, serving healthcare providers in over 150 countries.

Where is Teleflex Incorporated headquartered?

Teleflex Incorporated is headquartered in Wayne, Pennsylvania, USA.

How many people does Teleflex employ?

Teleflex employs approximately 12,000 people worldwide.

What are the main segments of Teleflex's business?

Teleflex operates in seven main segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and other.

What percentage of Teleflex’s revenue comes from the United States?

About 60% of Teleflex’s revenue comes from the United States.

What recent acquisitions has Teleflex made?

Teleflex recently acquired Palette Life Sciences AB to bolster its portfolio and operational efficiencies.

What is the UroLift™ System?

The UroLift™ System is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that helps preserve patient quality of life.

What was Teleflex's revenue growth in 2023?

Teleflex achieved a 6.5% constant currency revenue growth in 2023.

How can one access Teleflex's investor conference calls?

Teleflex's investor conference calls can be accessed via a live audio webcast on their website, teleflex.com.

What is the mission of Teleflex Incorporated?

Teleflex's mission is to provide solutions that improve outcomes and enhance safety for patients and healthcare providers.

Teleflex Incorporated

NYSE:TFX

TFX Rankings

TFX Stock Data

8.83B
46.31M
0.28%
99.65%
1.42%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
WAYNE